Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1909 |
Name | melanoma |
Definition | A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer melanoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00338377 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT00492505 | Phase II | Cisplatin + Sorafenib + Tamoxifen | Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma | Unknown status | USA | 0 |
NCT00538005 | Phase Ib/II | Bevacizumab + Oxaliplatin + Sorafenib | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | Unknown status | USA | 0 |
NCT00700882 | Phase II | Dasatinib | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00925132 | Phase Ib/II | Decitabine + Panobinostat + Temozolomide | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | Terminated | USA | 0 |
NCT00976573 | Phase II | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Everolimus + Paclitaxel | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | Completed | USA | 0 |
NCT01028222 | Phase II | Nilotinib | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation | Completed | USA | ITA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT01176474 | Phase I | NY-ESO-1 peptide vaccine Ipilimumab Nivolumab | A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | Completed | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01239134 | Phase I | TRX518 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Completed | USA | 0 |
NCT01258855 | Phase II | Aldesleukin Aflibercept | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01274338 | Phase III | Ipilimumab Interferon alpha-2b | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01303341 | Phase I | Riluzole + Sorafenib | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | Active, not recruiting | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01321437 | Phase II | Axitinib | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Completed | USA | 0 |
NCT01323517 | Phase II | Dactinomycin + Ipilimumab + Melphalan | Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | Completed | USA | 0 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT01358331 | Phase I | MK-8353 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | Terminated | 0 | |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01409174 | Phase Ib/II | Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | Terminated | USA | 0 |
NCT01425008 | Phase I | Tovorafenib | Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma | Completed | USA | GBR | 0 |
NCT01436656 | Phase I | Encorafenib | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Completed | USA | FRA | ESP | AUS | 3 |
NCT01449279 | Phase I | Ipilimumab | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | Completed | USA | 0 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01495988 | Phase II | Bevacizumab Vemurafenib | Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | Terminated | USA | 0 |
NCT01497808 | Phase Ib/II | Ipilimumab | RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma | Completed | USA | 0 |
NCT01512251 | Phase Ib/II | Buparlisib + Vemurafenib | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | Completed | USA | 0 |
NCT01519323 | Phase I | Vemurafenib | BRIM-P | Terminated | USA | ITA | GBR | FRA | ESP | DEU | AUS | 3 |
NCT01533948 | Phase II | Axitinib | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT01543698 | Phase Ib/II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | CAN | BEL | AUS | 2 |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01565837 | Phase II | Ipilimumab | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | Unknown status | USA | 0 |
NCT01585415 | Phase I | Vandetanib | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | Terminated | USA | 0 |
NCT01586195 | Phase II | Vemurafenib | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | Terminated | USA | 0 |
NCT01603212 | Phase Ib/II | Aldesleukin + Alpha 2 Interferon + Vemurafenib | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | Completed | USA | 0 |
NCT01619774 | Phase II | Dabrafenib + Trametinib | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | Completed | USA | 0 |
NCT01621490 | Phase I | Ipilimumab Nivolumab | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) | Completed | USA | ESP | 1 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01638676 | Phase Ib/II | Metformin + Vemurafenib | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | Recruiting | USA | 0 |
NCT01656642 | Phase I | Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Vemurafenib | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | Completed | USA | 0 |
NCT01657591 | Phase I | Vemurafenib + XL888 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | Completed | USA | 0 |
NCT01659151 | Phase II | Aldesleukin Fludarabine Vemurafenib | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT01667419 | Phase III | Vemurafenib | BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 19 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT01682083 | Phase III | Dabrafenib + Trametinib | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 15 |
NCT01682213 | Phase II | Dabrafenib | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | Completed | USA | 0 |
NCT01683188 | Phase III | Aldesleukin + Vemurafenib | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma | Terminated | USA | 0 |
NCT01689974 | Phase II | Ipilimumab | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | Terminated | USA | 0 |
NCT01696045 | Phase II | Ipilimumab | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | Terminated | USA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT01701037 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | Terminated | USA | 0 |
NCT01701674 | Phase I | Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Active, not recruiting | USA | 0 |
NCT01703507 | Phase I | Ipilimumab | Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases | Completed | USA | 0 |
NCT01708941 | Phase II | Interferon alpha-2b Ipilimumab | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01721603 | Phase II | Dabrafenib | A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases | Terminated | USA | 0 |
NCT01726738 | Phase II | Dabrafenib + Trametinib | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | Completed | USA | 0 |
NCT01738139 | Phase I | Imatinib + Ipilimumab | Ipilimumab and Imatinib Mesylate in Advanced Cancer | Active, not recruiting | USA | 0 |
NCT01740297 | Phase Ib/II | Ipilimumab Talimogene laherparepvec | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | Completed | USA | FRA | DEU | 0 |
NCT01754376 | Phase II | Aldesleukin + Vemurafenib | Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma | Terminated | USA | 0 |
NCT01763164 | Phase III | Dacarbazine Binimetinib | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 17 |
NCT01765543 | Phase I | Rifampin + Vemurafenib | A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | Completed | USA | 4 |
NCT01767454 | Phase I | Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | Completed | USA | 0 |
NCT01777776 | Phase Ib/II | Encorafenib Encorafenib + Ribociclib | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | Terminated | USA | CAN | AUS | 1 |
NCT01781026 | Phase II | Vemurafenib | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | Completed | USA | 0 |
NCT01781572 | Phase Ib/II | Binimetinib + Ribociclib | A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | Completed | USA | ITA | DEU | AUS | 1 |
NCT01810016 | Phase I | Ipilimumab NY-ESO-1 peptide vaccine | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | Terminated | USA | AUS | 0 |
NCT01813214 | Phase II | Vemurafenib | The Effects of Vemurafenib on Immunity in Patients With Melanoma | Terminated | USA | 0 |
NCT01820364 | Phase II | Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib Encorafenib + Infigratinib Capmatinib + Encorafenib | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma | Terminated | USA | ESP | DEU | CAN | AUS | 1 |
NCT01826448 | Phase I | Pexidartinib + Vemurafenib | A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma | Terminated | USA | FRA | DEU | 0 |
NCT01827111 | Phase II | Ipilimumab + Nab-paclitaxel | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT01835184 | Phase I | Cabozantinib + Vemurafenib | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT01841463 | Phase Ib/II | Vemurafenib + Voruciclib | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation | Suspended | USA | 0 |
NCT01843738 | Phase I | Vemurafenib | Radiation Use During Vemurafenib Treatment | Withdrawn | USA | 0 |
NCT01844674 | Phase I | Tizanidine + Vemurafenib | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | Completed | USA | CAN | 3 |
NCT01876212 | Phase II | Dasatinib | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | Completed | USA | 0 |
NCT01876641 | Phase Ib/II | Decitabine + Vemurafenib | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib | Terminated | USA | 0 |
NCT01894672 | Phase II | Encorafenib | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | Completed | USA | 0 |
NCT01897116 | Phase I | Hydroxychloroquine + Vemurafenib | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | Completed | USA | 0 |
NCT01902173 | Phase Ib/II | Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | Active, not recruiting | USA | 0 |
NCT01904123 | Phase I | WP1066 | A Phase I Trial of WP1066 | Completed | USA | 0 |
NCT01909453 | Phase III | Vemurafenib Encorafenib Binimetinib + Encorafenib | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 21 |
NCT01940809 | Phase II | Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT01941927 | Phase II | Trametinib + Uprosertib | Trametinib With GSK2141795 in BRAF Wild-type Melanoma | Completed | USA | 0 |
NCT01942993 | Phase II | Vemurafenib | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | Terminated | USA | 0 |
NCT01943422 | Phase Ib/II | Interferon alpha-2b + Vemurafenib | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | Completed | USA | 0 |
NCT01946789 | Phase I | ALT-803 | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01950195 | Phase I | Ipilimumab | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | Terminated | USA | 0 |
NCT01950390 | Phase II | Ipilimumab Bevacizumab + Ipilimumab | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01955460 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | Recruiting | USA | 0 |
NCT01961115 | Phase II | Epacadostat MELITAC 12.1 Peptide Vaccine | INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Completed | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | AUS | 1 |
NCT01967823 | Phase II | Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | Completed | USA | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 6 |
NCT01970358 | Phase I | NeoVax melanoma vaccine | A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | Completed | USA | 0 |
NCT01970527 | Phase II | Ipilimumab | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | Terminated | USA | 0 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01978236 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | Terminated | USA | AUS | 0 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | AUS | 2 |
NCT01989585 | Phase Ib/II | Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT01993719 | Phase II | Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide | Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02009397 | Phase Ib/II | Sargramostim Ipilimumab | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | Completed | USA | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02012231 | Phase Ib/II | PLX8394 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | Terminated | USA | 0 |
NCT02013804 | Phase I | MEDI0680 | A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02020707 | Phase I | Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02027935 | Phase II | Aldesleukin Cyclophosphamide Ipilimumab | Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 | Active, not recruiting | USA | 0 |
NCT02027961 | Phase Ib/II | Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | Completed | USA | ITA | FRA | CAN | 0 |
NCT02032810 | Phase I | Panobinostat Ipilimumab | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Completed | USA | 0 |
NCT02036086 | Phase II | Cobimetinib + Vemurafenib | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | Active, not recruiting | CAN | 0 |
NCT02039947 | Phase II | Dabrafenib + Trametinib | Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUS | 0 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |
NCT02047747 | Phase II | Dacomitinib | A Phase II Study of Dacomitinib in Progressive Brain Metastases | Terminated | USA | 0 |
NCT02050321 | Phase II | Acitretin + Vemurafenib | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | Terminated | USA | 0 |
NCT02054520 | Phase II | Ipilimumab | Immunotherapy Study for Patients With Stage IV Melanoma | Terminated | USA | 0 |
NCT02065466 | Phase Ib/II | Bevacizumab + Nab-paclitaxel + Temozolomide | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | Withdrawn | USA | 0 |
NCT02068079 | Phase I | Trientine + Vemurafenib | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | Withdrawn | USA | 0 |
NCT02073123 | Phase Ib/II | Ipilimumab Indoximod | Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02089685 | Phase Ib/II | Ipilimumab Peginterferon alfa-2b Pembrolizumab | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Completed | 0 | |
NCT02094872 | Phase II | Doxorubicin | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | Completed | USA | 0 |
NCT02097225 | Phase I | Dabrafenib + Onalespib + Trametinib | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02097732 | Phase II | Ipilimumab | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | Terminated | USA | 0 |
NCT02107755 | Phase II | Ipilimumab | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | Unknown status | USA | 0 |
NCT02110355 | Phase Ib/II | KRT-232 + Trametinib Dabrafenib + KRT-232 + Trametinib Dabrafenib + Trametinib | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | Completed | USA | AUS | 0 |
NCT02112032 | Phase I | Peginterferon alfa-2b + Pembrolizumab | Treatment of Advanced Melanoma With MK-3475 and Peginterferon | Completed | USA | 0 |
NCT02115243 | Phase I | Ipilimumab | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | Completed | USA | 0 |
NCT02117362 | Phase I | Ipilimumab Belapectin | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02120222 | Phase I | Selinexor | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02126579 | Phase Ib/II | Poly ICLC Long peptide vaccine 7 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | Completed | USA | 0 |
NCT02129075 | Phase II | NeoVax melanoma vaccine CDX-301 Rasdegafusp alfa | CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma | Completed | USA | 0 |
NCT02130466 | Phase Ib/II | Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | Completed | 0 | |
NCT02138292 | Phase I | Digoxin + Trametinib | A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | Completed | USA | 0 |
NCT02141542 | Phase I | Tremelimumab MEDI3617 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | Completed | USA | 0 |
NCT02142218 | Phase I | Nivolumab | Expanded Access Program With Nivolumab to Treat Melanoma | No longer available | USA | CAN | 4 |
NCT02143050 | Phase Ib/II | Dabrafenib + Metformin + Trametinib | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | Withdrawn | USA | 0 |
NCT02145910 | Phase I | Vemurafenib | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | Withdrawn | 0 | |
NCT02156804 | Phase II | Nivolumab | A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) | Completed | ITA | GBR | ESP | DEU | BEL | AUT | 14 |
NCT02158520 | Phase II | Ipilimumab Bevacizumab + Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02159066 | Phase II | Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | Completed | USA | ITA | GBR | ESP | DEU | CAN | AUS | 2 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02186249 | Phase III | Ipilimumab + Nivolumab | Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) | No longer available | USA | CAN | 0 |
NCT02196181 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02200562 | Phase Ib/II | Dabrafenib + Ipilimumab | Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma | Terminated | USA | 0 |
NCT02210104 | Phase I | Ipilimumab Cyclophosphamide | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Withdrawn | 0 | |
NCT02224781 | Phase III | Ipilimumab + Nivolumab Dabrafenib + Trametinib | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | Active, not recruiting | USA | 0 |
NCT02230306 | Phase II | Cobimetinib + Vemurafenib | Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | Terminated | USA | 0 |
NCT02231775 | Phase II | Dabrafenib + Trametinib | Combi-Neo Study for Stage IV Melanoma | Active, not recruiting | USA | 0 |
NCT02257424 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) | Completed | USA | 0 |
NCT02259231 | Phase Ib/II | Ipilimumab Nivolumab Omaveloxolone | RTA 408 Capsules in Patients With Melanoma - REVEAL | Completed | USA | 0 |
NCT02263508 | Phase Ib/II | Pembrolizumab Talimogene laherparepvec | MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 11 |
NCT02263898 | Phase II | Binimetinib + Encorafenib | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | Withdrawn | USA | 0 |
NCT02272855 | Phase II | Canerpaturev + Ipilimumab | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma | Completed | USA | 0 |
NCT02296112 | Phase II | Trametinib | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | Completed | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02300935 | Phase I | Nab-paclitaxel + Trametinib | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | Withdrawn | USA | 0 |
NCT02302339 | Phase II | Glembatumumab vedotin | A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma | Terminated | USA | 0 |
NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
NCT02306850 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | Completed | USA | 0 |
NCT02307149 | Phase I | Coxsackievirus A21 Ipilimumab | Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma | Completed | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | FRA | ESP | CAN | BEL | AUT | AUS | 1 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | FRA | 2 |
NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
NCT02320058 | Phase II | Ipilimumab + Nivolumab | A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) | Completed | USA | 0 |
NCT02320305 | Phase I | MART-1 antigen GLA-SE + MART-1 antigen | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | Completed | USA | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02332668 | Phase Ib/II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Recruiting | USA | ITA | GBR | FRA | DEU | AUS | 5 |
NCT02334735 | Phase II | Poly ICLC Autologous Dendritic Cells Pulsed with MART-1 NY-ESO-1 peptide vaccine | A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | Completed | USA | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02339324 | Phase I | Interferon alpha-2b Pembrolizumab | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | Completed | USA | 0 |
NCT02339571 | Phase II | Sargramostim Nivolumab Ipilimumab | Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | 1 |
NCT02360579 | Phase II | LN-144 | Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 2 |
NCT02362594 | Phase III | Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) | Active, not recruiting | 0 | |
NCT02381314 | Phase I | Ipilimumab + MGA271 | Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer | Completed | USA | 0 |
NCT02382549 | Phase I | 6MHP vaccine + Dabrafenib + Trametinib | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61) | Recruiting | USA | 0 |
NCT02385669 | Phase Ib/II | 6MHP vaccine Ipilimumab | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | Terminated | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02388906 | Phase III | Nivolumab Ipilimumab | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 16 |
NCT02400385 | Phase II | Nivolumab + Sunitinib | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | Withdrawn | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | 8 |
NCT02407171 | Phase Ib/II | Pembrolizumab | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Completed | USA | 0 |
NCT02413827 | Phase Ib/II | Nivolumab + Varlilumab Rasdegafusp alfa Poly ICLC | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | Terminated | USA | 0 |
NCT02423863 | Phase II | Poly ICLC | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol | Completed | USA | 0 |
NCT02425306 | Phase Ib/II | Cyclophosphamide 6MHP vaccine Poly ICLC | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | Terminated | USA | 0 |
NCT02427893 | Phase III | Cobimetinib Vemurafenib | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | Withdrawn | USA | 0 |
NCT02428712 | Phase Ib/II | PLX8394 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02434354 | Phase I | Pembrolizumab | A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma | Completed | USA | 0 |
NCT02437136 | Phase Ib/II | Entinostat + Pembrolizumab | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma | Completed | USA | 0 |
NCT02452281 | Phase Ib/II | Vitespen Ipilimumab | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | Withdrawn | USA | 0 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02475213 | Phase I | MGA271 + Pembrolizumab | Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer | Completed | USA | 0 |
NCT02493361 | Phase II | Pembrolizumab IL-12 gene | Trial of pIL-12/MK-3475 in Metastatic Melanoma | Completed | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02500576 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab | MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2) | Completed | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | ESP | 1 |
NCT02506153 | Phase III | Interferon alpha-2b Pembrolizumab | High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | Active, not recruiting | USA | CAN | 1 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | ESP | DEU | BEL | AUT | AUS | 3 |
NCT02519322 | Phase II | Ipilimumab Nivolumab | Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma | Completed | USA | 0 |
NCT02521870 | Phase I | Pembrolizumab SD-101 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma | Terminated | USA | DEU | AUS | 1 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | FRA | CAN | 1 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02553642 | Phase II | Nivolumab Ipilimumab | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Active, not recruiting | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | GBR | FRA | CAN | AUS | 3 |
NCT02557321 | Phase Ib/II | PV-10 Pembrolizumab | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02565992 | Phase I | Coxsackievirus A21 + Pembrolizumab | Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma | Completed | USA | 0 |
NCT02574533 | Phase I | Pembrolizumab FANG vaccine | Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma | Completed | USA | 0 |
NCT02575404 | Phase I | Belapectin Pembrolizumab | GR-MD-02 Plus Pembrolizumab in Melanoma Patients | Completed | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 22 |
NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
NCT02591654 | Phase I | Pembrolizumab | MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma | Terminated | USA | 0 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Active, not recruiting | USA | 0 |
NCT02599402 | Phase III | Ipilimumab + Nivolumab Nivolumab | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | Completed | ITA | GBR | FRA | DEU | BEL | AUT | AUS | 5 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Active, not recruiting | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | ITA | CAN | 6 |
NCT02617849 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | Active, not recruiting | CAN | 0 |
NCT02621021 | Phase II | Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin | A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | Suspended | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02637531 | Phase I | Pembrolizumab Eganelisib | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Active, not recruiting | USA | 0 |
NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Active, not recruiting | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02644967 | Phase Ib/II | IMO-2125 + Ipilimumab IMO-2125 + Pembrolizumab | A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | AUS | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02652455 | Phase I | Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | Completed | USA | 0 |
NCT02656706 | Phase II | Ipilimumab + Nivolumab | BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial | Active, not recruiting | USA | 0 |
NCT02659540 | Phase I | Ipilimumab + Nivolumab | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Completed | USA | 0 |
NCT02681549 | Phase II | Bevacizumab + Pembrolizumab | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02706353 | Phase Ib/II | APX005M + Pembrolizumab | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02711345 | Phase I | LTT462 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers | Terminated | USA | ESP | DEU | 3 |
NCT02714218 | Phase III | Ipilimumab + Nivolumab | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 5 |
NCT02716948 | Phase I | Nivolumab | Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Completed | USA | 0 |
NCT02718066 | Phase Ib/II | Chidamide + Nivolumab | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02719015 | Phase Ib/II | Pembrolizumab + rAd-hCD40L | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | Withdrawn | 0 | |
NCT02721459 | Phase I | Cobimetinib + Vemurafenib + XL888 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | Active, not recruiting | USA | 0 |
NCT02723006 | Phase I | Nivolumab + Tovorafenib MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | Terminated | USA | 0 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | ITA | FRA | ESP | CAN | AUS | 3 |
NCT02736123 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | Withdrawn | USA | 0 |
NCT02740920 | Phase II | Pembrolizumab | Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker | Terminated | CAN | 0 |
NCT02743819 | Phase II | Ipilimumab + Pembrolizumab | Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody | Active, not recruiting | USA | 0 |
NCT02748564 | Phase II | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Terminated | USA | 0 |
NCT02752074 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 14 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02796352 | Phase II | Aldesleukin | A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study | Terminated | USA | 0 |
NCT02799095 | Phase I | ALKS 4230 | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | Active, not recruiting | USA | ESP | CAN | BEL | AUS | 2 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | BEL | 5 |
NCT02812693 | Phase Ib/II | Imatinib + Pembrolizumab | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | Withdrawn | 0 | |
NCT02816021 | Phase II | Azacitidine + Pembrolizumab | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
NCT02819843 | Phase II | Talimogene laherparepvec | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | Active, not recruiting | USA | 0 |
NCT02823405 | Phase I | Pembrolizumab + X4P-001 | Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA) | Completed | USA | 0 |
NCT02839694 | Phase I | Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | Withdrawn | 0 | |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02857569 | Phase Ib/II | Ipilimumab + Nivolumab | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT) | Completed | FRA | 0 |
NCT02858869 | Phase 0 | Pembrolizumab | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | Active, not recruiting | USA | 0 |
NCT02870244 | Phase I | Autologous TIL 13831 TCR transduced T cells | Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | Recruiting | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02889861 | Phase Ib/II | Tebentafusp | IMCgp100-401 Rollover Study | Terminated | USA | GBR | 0 |
NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
NCT02908672 | Phase III | Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 10 |
NCT02910700 | Phase II | Nivolumab + Trametinib Dabrafenib + Nivolumab + Trametinib | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma | Suspended | USA | 0 |
NCT02915666 | Phase I | Dabrafenib + Digoxin + Trametinib | A Clinical Trial of Patients With Melanoma | Withdrawn | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | 1 |
NCT02935790 | Phase I | Citarinostat + Ipilimumab + Nivolumab | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | Completed | USA | 0 |
NCT02939300 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma | Completed | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02961283 | Phase I | ASN003 | Study of ASN003 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02965716 | Phase II | Pembrolizumab + Talimogene laherparepvec | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |
NCT02967692 | Phase III | Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 19 |
NCT02970981 | Phase II | Ipilimumab + Nivolumab | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | Completed | USA | 0 |
NCT02974725 | Phase I | LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUS | 4 |
NCT02974803 | Phase II | Dabrafenib + Trametinib | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | Terminated | CAN | 0 |
NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
NCT02981303 | Phase II | Pembrolizumab + PGG beta-glucan | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02983006 | Phase I | DS-8273a + Nivolumab | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | Completed | USA | 0 |
NCT02983045 | Phase Ib/II | Nivolumab + NKTR-214 | A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) | Completed | USA | ITA | GBR | FRA | ESP | CAN | BEL | 1 |
NCT02989064 | Phase I | MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Completed | USA | ESP | CAN | 0 | |
NCT02990416 | Phase Ib/II | A-dmDT390-bisFv(UCHT1) + Pembrolizumab | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | Unknown status | USA | 0 |
NCT03003676 | Phase I | Cyclophosphamide + ONCOS-102 + Pembrolizumab | A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade | Completed | USA | 1 |
NCT03005639 | Phase II | Cobimetinib + Vemurafenib | ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma | Withdrawn | USA | 0 |
NCT03021460 | Phase II | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03025256 | Phase I | Nivolumab | Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) | Active, not recruiting | USA | 0 |
NCT03026517 | Phase I | Dabrafenib + Phenformin + Trametinib | Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | Active, not recruiting | USA | 0 |
NCT03033576 | Phase II | Ipilimumab Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03050060 | Phase II | Nelfinavir + Nivolumab | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | Terminated | USA | 0 |
NCT03068455 | Phase III | Nivolumab Ipilimumab Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 9 |
NCT03088176 | Phase I | Dabrafenib + Talimogene laherparepvec + Trametinib | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | Unknown status | USA | 0 |
NCT03089606 | Phase II | Pembrolizumab | Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker | Completed | USA | 0 |